

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-15** | Period of Report: **2013-01-15**
SEC Accession No. [0001011060-13-000002](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

AdvanSource Biomaterials Corp

CIK: **1011060** | IRS No.: **043186647** | State of Incorporation: **DE** | Fiscal Year End: **0331**
Type: **8-K** | Act: **34** | File No.: **001-11737** | Film No.: **13529936**
SIC: **3841** Surgical & medical instruments & apparatus

Mailing Address
229 ANDOVER STREET
WILMINGTON MA 01887

Business Address
229 ANDOVER STREET
WILMINGTON MA 01887
978-657-0075

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549**

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): January 15, 2013 (January 11, 2013)

AdvanSource Biomaterials Corporation
(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-28034
(Commission File Number)

04-3186647
(IRS Employer
Identification No.)

229 Andover Street, Wilmington, Massachusetts, 01887
(Address of Principal Executive Offices) (Zip Code)

(978) 657-0075
(Registrant's telephone number, including area code)

(Former name, former address and former fiscal year, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 4.01. Change in Registrant's Certifying Accountant

On January 11, 2013, AdvanSource Biomaterials Corporation (the "Company"), based on the decision of the Audit Committee of its Board of Directors, dismissed Moody, Famiglietti & Andronico, LLP ("MFA") as the Company's independent registered public accounting firm and recommended, and approved, the engagement of Liggett, Vogt & Webb P.A. ("LVW") to serve as the Company's independent registered public accounting firm for the fiscal year ending March 31, 2013.

MFA's report on the Company's financial statements for the fiscal year ended March 31, 2012 did not contain an adverse opinion or disclaimer of opinion, nor was it qualified or modified as to uncertainty, audit scope or accounting principles.

During the fiscal year ended March 31, 2012 and through the date of dismissal, there were no disagreements with MFA on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure which, if not resolved to MFA's satisfaction, would have caused them to make reference to the subject matter in connection with their report on the Company's consolidated financial statements for such fiscal year; and there were no reportable events, as listed in Item 304(a)(1)(v) of Regulation S-K.

The Company provided MFA with a copy of the disclosures in the preceding two paragraphs and requested in writing that MFA furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not they agree with such disclosures. MFA provided a letter, dated January 15, 2013 stating its agreement with such statements, which is included as an exhibit to this Form 8-K.

During the fiscal years ended March 31, 2011 and 2012 and through the date of the Audit Committee's decision, the Company did not consult LVW with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements, or any other matter or reportable events listed in Items 304(a)(2)(i) and (ii) of Regulation S-K.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
16.1	Letter from Moody, Famiglietti & Andronico, LLP to the Securities and Exchange Commission dated January 15, 2013 with respect to the disclosure in this Form 8-K.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ADVANSOURCE BIOMATERIALS CORPORATION

By: /s/ Michael F. Adams
Michael F. Adams
President & CEO

Dated: January 15, 2013




EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
16.1	Letter from Moody, Famiglietti & Andronico, LLP to the Securities and Exchange Commission dated January 15, 2013 with respect to the disclosure in this Form 8-K.

January 15, 2013

Securities and Exchange Commission
Washington, D.C. 20549

Ladies and Gentlemen:

We were previously principal accountants for AdvanSource Biomaterials Corporation (herein referred to as “AdvanSource”) and, under the date of July 11, 2012, we reported on the consolidated financial statements of AdvanSource as of and for the year ended March 31, 2012. On January 11, 2013, we were dismissed. We have read AdvanSource’s statements included under Item 4.01 of its Form 8-K dated January 15, 2013, and we agree with such statements, except that we are not in a position to agree or disagree with the following statements:

- That, “AdvanSource Biomaterials Corporation (the “Company”), based on the decision of the Audit Committee of its Board of Directors, ...recommended and approved, the engagement of Liggett, Vogt & Webb P.A. (“LVW”) to serve as the Company’s independent registered public accounting firm for the fiscal year ending March 31, 2013.”
- That, “During the fiscal years ended March 31, 2011 and 2012 and through the date of the Audit Committee’s decision, the Company did not consult LVW with respect to the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, or any other matter or reportable events listed in Items 304(a)(2)(i) and (ii) of Regulation S-K.”

Very truly yours,

/s/ Moody, Famiglietti & Andronico, LLP

MFA - Moody, Famiglietti & Andronico, LLP